Timothy Rolph, Chief Scientific Officer at Akero Therapeutics, Inc. (AKRO), sold 46,850 shares at $55.04 ($2.5M) on 2025-06-06, disclosed to the SEC on 2025-06-09.
Scheduled sale ($2.5M) by Chief Scientific Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $53.37 | 9,350 | $499K | 19.6% |
| 2 | $53.37 | 9,350 | $499K | 19.6% |
| 3 | $53.84 | 3,150 | $170K | 6.7% |
| 4 | $55.04 | 25,000 | $1.4M | 54.1% |
| Total | $54.29 avg | 46,850 | $2.5M | 100% |
| Filing → |
| AKRO | SELL | 2025-09-10 | $1.1M | — | Filing → |
| AKRO | SELL | 2025-08-07 | $1.2M | — | Filing → |
| AKRO | SELL | 2025-07-09 | $1.2M | — | Filing → |